Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study to evaluate the safety of cellular adoptive immunotherapy using genetically modified and unmodified autologous CD8+ tyrosinase-specific T cells for patients with metastatic melanoma

Next Previous
Trial Profile

Phase I study to evaluate the safety of cellular adoptive immunotherapy using genetically modified and unmodified autologous CD8+ tyrosinase-specific T cells for patients with metastatic melanoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lymphokine-activated killer cells (Primary) ; Interleukin-2
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 10 May 2010 Biomarkers information updated
  • 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top